Business Wire7h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Smart patch combines real-time health monitoring and drug delivery
A DGIST research team, led by Professor Kyung-In Jang, has developed a smart patch capable of real-time biometric signal ...
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Insight News1d
Attorney General Keith Ellison secures $35 Novo Nordisk insulin for Minnesotans
For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.
Insulin Pen And Pump Market Expansion Forecasted At 6.97% CAGR To 60.0 Billion USD By 2032 Abbott Laboratories, Roche
Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...